Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results

• Tipo: Artigo em Revista Científica Internacional
• Data: 2017

Autores

Cardoso, PN (Autor) Outra; Pinheiro, AF (Autor) Outra; Meira, J (Autor) Outra; Pedrosa, AC (Autor) Outra; Manuel Falcão (Autor) FMUP; Pinheiro Costa, J (Autor) Outra; Falcão-Reis F (Autor) FMUP; Ângela Carneiro (Autor) FMUP

Revista

Título: Journal of Ophthalmology

Vol. 2017

Páginas: 1-6

ISSN: 2090-004X

Editora: Hindawi

Indexação

ISI Web of Knowledge - 8 Citações

Scopus - 10 Citações

Outras Informações

ID Authenticus: P-00N-6KZ

DOI: 10.1155/2017/6835782

Abstract (EN): Purpose. To report the long-term clinical outcomes after switching from intravitreal bevacizumab or ranibizumab to aflibercept therapy in eyes with AMD. Methods. Retrospective analysis of changes in BCVA, SD-OCT image, and frequency of injections after 1, 2, and 3 years of follow-up. Results. 164 eyes were analyzed, 101 eyes switched from bevacizumab (group 1) and 63 from ranibizumab (group 2). One year after the switch, there was an overall nonsignificant mean decrease of 2 ETDRS letters in BCVA. Three years after, there was an overall mean decrease of 7 ETDRS letters, which was statistically significant. A significant improvement in the mean CRT was found at 1, 2, and 3 years. There was a significant decrease in the mean number of injections per year (7.8 to 6.5, p < 0.005) between the first and third year. Conclusion. Aflibercept can be useful in the management of refractory neovascular AMD, with a good morphological response. However, in the long-term, BCVA stabilization was not achieved.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 6